Deepinder Goyal’s 'Continue' launches $25 million fund to support human ageing research

Zomato founder and CEO Deepinder Goyal has announced the launch of a $25 million fund under his research initiative Continue, aimed at supporting scientists studying the fundamental mechanisms of human ageing. The fund will be entirely personally financed by Goyal, he said in a post on X.

Called 'Continue Research', the fund will provide grants to researchers worldwide who are exploring what Goyal describes as “simpler questions” in biology — ideas that challenge the complexity of existing models around ageing.

In the post announcing the fund, Goyal said Continue began two years ago as a research effort based on the belief that “if the human body is a system, it should also have its leverage points — simple levers that, when adjusted, could fundamentally alter how we age and live.”

So many people keep asking me about Continue. What is it? What are you up to? Here you go...

Continue started as a research effort two years ago, with the belief that if the human body is a system, it should also have its leverage points. The simple levers that, when adjusted,…

— Deepinder Goyal (@deepigoyal) October 24, 2025

The research team, he said, has been investigating a hypothesis about ageing that could “fundamentally change our understanding of biology and ageing” if proven true.

“Today, we are expanding Continue Research to include a $25 million fund (entirely personally backed) to support researchers across the world who dare to ask simpler questions than anyone else, who believe biology might be far simpler than we’ve made it,” Goyal wrote.

According to the Continue website, the fund will support two types of projects:

• Moonshots, offering between $50,000 and $250,000 for high-risk, early-stage ideas that could reshape existing biological understanding.


• Deep Dives, with funding between $250,000 and $2 million for researchers seeking to validate or disprove promising hypotheses over one to three years.

A key condition for funding is that all research outcomes — including raw data, protocols, and failed experiments — must be made open source and publicly accessible. Continue will not require prior publications or impose oversight and will fund projects based on their potential to advance fundamental science.

Continue Research positions itself as neither a company nor a startup but as “a research team and seed fund for the next phase of human existence.” Goyal said the initiative’s focus is not on defeating death but on extending healthy human function to help society make longer-term, more sustainable decisions.

“The goal is to extend healthy human function long enough that humans stop making short-term decisions. This work will likely take decades to bear fruit. The primary beneficiaries will be generations that come after us, not us," he wrote.

He also clarified that Continue is not a part of Eternal.Read about our editorial guidelines and ethics policy